IFP Advisors’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $108K | Hold |
341
| – | – | ﹤0.01% | 1931 |
|
|
2026
Q1 | $68.1K | Sell |
341
-1
| -0.3% | -$198 | ﹤0.01% | 2079 |
|
|
2025
Q4 | $64.7K | Buy |
342
+312
| +1,040% | +$59.9K | ﹤0.01% | 2044 |
|
|
2025
Q3 | $5.31K | Sell |
30
-5
| -14% | -$743 | ﹤0.01% | 3215 |
|
|
2025
Q2 | $6.71K | Buy |
35
+26
| +289% | +$2.78K | ﹤0.01% | 3165 |
|
|
2025
Q1 | $1.16K | Buy |
+9
| New | +$1.02K | ﹤0.01% | 3303 |
|
|
2024
Q4 | – | Hold |
0
| – | – | – | 4004 |
|
|
2023
Q1 | – | Sell |
-30
| Closed | -$6K | – | 3989 |
|
|
2022
Q4 | $6K | Sell |
30
-23
| -43% | -$1.5K | ﹤0.01% | 3703 |
|
|
2022
Q3 | $7K | Hold |
53
| – | – | ﹤0.01% | 3862 |
|
|
2022
Q2 | $7K | Hold |
53
| – | – | ﹤0.01% | 3606 |
|
|
2022
Q1 | $7K | Buy |
53
+47
| +783% | +$3.41K | ﹤0.01% | 3605 |
|
|
2021
Q4 | $1K | Hold |
6
| – | – | ﹤0.01% | 3046 |
|
|
2021
Q3 | $1K | Hold |
6
| – | – | ﹤0.01% | 3058 |
|
|
2021
Q2 | $1K | Sell |
6
-2
| -25% | -$166 | ﹤0.01% | 2914 |
|
|
2021
Q1 | $1K | Buy |
8
+2
| +33% | +$189 | ﹤0.01% | 2841 |
|
|
2020
Q4 | $0 | Sell |
6
-50
| -89% | -$2.85K | ﹤0.01% | 3029 |
|
|
2020
Q3 | $3K | Hold |
56
| – | – | ﹤0.01% | 2369 |
|
|
2020
Q2 | $4K | Sell |
56
-151
| -73% | -$9.57K | ﹤0.01% | 2178 |
|
|
2020
Q1 | $10K | Sell |
207
-38
| -16% | -$2.15K | ﹤0.01% | 1774 |
|
|
2019
Q4 | $16K | Sell |
245
-250
| -51% | -$16.7K | ﹤0.01% | 1721 |
|
|
2019
Q3 | $29K | Buy |
+495
| New | +$31.1K | ﹤0.01% | 1602 |
|
|
2019
Q1 | – | Sell |
-103
| Closed | -$9K | – | 2945 |
|
|
2018
Q4 | $9K | Buy |
103
+21
| +26% | +$2.24K | ﹤0.01% | 2558 |
|
|
2018
Q3 | $14K | Sell |
82
-14
| -15% | -$2.11K | ﹤0.01% | 2658 |
|
|
2018
Q2 | $12K | Sell |
96
-37
| -28% | -$4.13K | ﹤0.01% | 2784 |
|
|
2018
Q1 | $11K | Hold |
133
| – | – | ﹤0.01% | 2732 |
|
|
2017
Q4 | $11K | Sell |
133
-239
| -64% | -$20.7K | ﹤0.01% | 2771 |
|
|
2017
Q3 | $32K | Sell |
372
-18
| -5% | -$1.43K | ﹤0.01% | 2296 |
|
|
2017
Q2 | $30K | Sell |
390
-165
| -30% | -$11.5K | ﹤0.01% | 2317 |
|
|
2017
Q1 | $37K | Buy |
555
+422
| +317% | +$27.8K | ﹤0.01% | 2108 |
|
|
2016
Q4 | $8K | Sell |
133
-32
| -19% | -$2.02K | ﹤0.01% | 3041 |
|
|
2016
Q3 | $11K | Sell |
165
-45
| -21% | -$3.3K | ﹤0.01% | 2771 |
|
|
2016
Q2 | $16K | Buy |
+210
| New | +$15.6K | ﹤0.01% | 2489 |
|
|
2016
Q1 | – | Sell |
-200
| Closed | -$14K | – | 2942 |
|
|
2015
Q4 | $14K | Buy |
+200
| New | +$12.3K | ﹤0.01% | 2385 |
|
Other funds holding LGND
JT
CAM
IFP Advisors's LGND Position: Q2 2026 in Review
IFP Advisors held its Ligand Pharmaceuticals (LGND) position steady in Q2 2026 at 341 shares worth $108K. The position accounts for ﹤0.01% of the portfolio, ranked #1931.
IFP Advisors first reported a position in LGND in Q4 2015 and has held it in 32 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- IFP Advisors held 341 shares of Ligand Pharmaceuticals worth $108K as of Q2 2026.
- IFP Advisors left its Ligand Pharmaceuticals share count unchanged in Q2 2026.
- Ligand Pharmaceuticals made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #1931 holding.
- IFP Advisors first reported a position in Ligand Pharmaceuticals in Q4 2015 and has held it in 32 quarters since.
- 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.